HomeProductsBioactive CompoundsMetabolic EnzymesPDEGisadenafil
Chemical structure of CAS 334826-98-1

Gisadenafil

In Stock•Starting at $245 for 1 mg
CAS No.334826-98-1
MDL No.N/A
MFC23H33N7O5S
MW519.60
InChI KeyYPFZMBHKIVDSNR-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mgTo Be Confirmed$245In Stock
5 mgTo Be Confirmed$550In Stock
10 mgTo Be Confirmed$814In Stock
25 mgTo Be Confirmed$1294In Stock
50 mgTo Be Confirmed$1755In Stock
100 mgTo Be Confirmed$2351In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Gisadenafil is an organonitrogen heterocyclic compound.

CAS No.334826-98-1
Product NameGisadenafil

Biological Targets

PDE5A

Associated Conditions

chronic obstructive pulmonary disease·benign prostatic hyperplasia·Impotence·overactive bladder
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics.

Bioorganic & medicinal chemistry • Vol. 20, Issue 1 • 2012
PMID: 22100260DOI: 10.1016/j.bmc.2011.10.022

Application of physiologically based pharmacokinetic modeling to understanding the clinical pharmacokinetics of UK-369,003.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 39, Issue 7 • 2011
PMID: 21451120DOI: 10.1124/dmd.111.038224

A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder.

BJU international • Vol. 106, Issue 5 • 2010
PMID: 20151971DOI: 10.1111/j.1464-410X.2010.09205.x

A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.

BJU international • Vol. 106, Issue 5 • 2010
PMID: 20184577DOI: 10.1111/j.1464-410X.2010.09204.x

Documentation

Similar Products